Department of Oncology, Linfen People's Hospital, Linfen, China.
Department of Galactophore, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
J Int Med Res. 2023 Aug;51(8):3000605231171762. doi: 10.1177/03000605231171762.
CCL20 is a chemotactic factor that is involved in immune cell recruitment and cancer progression. However, the role of CCL20 in the prognosis of breast cancer remains unclear. This study analyzed correlations between CCL20 expression and immune infiltration, clinicopathological parameters, and prognosis in breast cancer patients.
Correlations between CCL20 expression and clinicopathological parameters, prognosis, and immune infiltration in breast cancer were determined using the TIMER, UALCAN, and PrognoScan databases. Furthermore, gene-gene and protein-protein interactions were determined using GeneMANIA and STING network construction, respectively.
CCL20 expression was significantly upregulated in breast cancer and had significant associations with clinicopathological features, including race, sex, age, menopause status, cancer stage, cancer subclass, and nodal metastasis; moreover, patients with higher CCL20 expression exhibited poor prognosis. Meanwhile, CCL20 expression was significantly correlated with the infiltration of immune cells in breast cancer, including monocytes, neutrophils, tumor-associated macrophages, Th1 cells, regulatory T cells, and exhausted T cells. Moreover, the network of CCL20 expression showed the majority genes and proteins were associated with immune reactions.
CCL20 is a prognosis-related biomarker in breast cancer on the basis of its correlation with immune infiltration levels and has potential to also be a therapeutic target.
CCL20 是一种趋化因子，参与免疫细胞募集和癌症进展。然而，CCL20 在乳腺癌预后中的作用尚不清楚。本研究分析了 CCL20 表达与乳腺癌患者免疫浸润、临床病理参数和预后之间的相关性。
使用 TIMER、UALCAN 和 PrognoScan 数据库确定 CCL20 表达与乳腺癌临床病理参数、预后和免疫浸润之间的相关性。此外，使用 GeneMANIA 确定基因-基因和蛋白质-蛋白质相互作用，分别使用 STING 网络构建。
CCL20 表达在乳腺癌中显著上调，与临床病理特征显著相关，包括种族、性别、年龄、绝经状态、癌症分期、癌症亚类和淋巴结转移；此外，CCL20 表达较高的患者预后较差。同时，CCL20 表达与乳腺癌中免疫细胞的浸润显著相关，包括单核细胞、中性粒细胞、肿瘤相关巨噬细胞、Th1 细胞、调节性 T 细胞和耗竭性 T 细胞。此外，CCL20 表达的网络显示大多数基因和蛋白质与免疫反应有关。
CCL20 是乳腺癌与免疫浸润水平相关的预后相关生物标志物，具有成为治疗靶点的潜力。
